TABLE 5.

The main uranium fission processing facilities and their ⁹⁹Mo supply capacities.

Processing facility a		Country	Target	Chemical process b	Estimated available supply capacity, six-day Ci/week	Production of 99Mo, week/year	Estimated available supply capacity by 2024 c , six-day Ci/year	Estimated global market share, %	Expected shutdown, year
Global producers	ANSTO	Australia	LEU	Alkaline	2,150	43	92,450	13	2057
	d ANM project				+1,350  C		+58,050  C	8
	e Curium	Netherlands	LEU	Alkaline	5,000	52	260,000	37	N.A
	IRE	Belgium	HEU	Alkaline process	3,500	49	171,500	24	2028
	NTP	South Africa	LEU	Alkaline	3,000	44	130,700	18	2030
	f CNL/Nordion	Canada	HEU	Acidic	29% (Global market)	N.A	N.A	N.A	stopped
	Mallinckrodt	Netherlands	HEU	Alkaline	24% (Global market)	N.A	N.A	N.A	stopped
Regional producers	RIAR	Russia	HEU	Alkaline	540	50	27,000	Domestic use	2025
	KAPROV		HEU	Alkaline	350	48	16,800	Domestic use	2025
	CNEA	Argentina	LEU	Alkaline	500	46	23,000	Domestic use	2027

The information is derived from: 1 NEA, 2019, 2 NAP, 2018.

^aANSTO: australian nuclear science and technology organization; ANM: ANSTO, nuclear medicine; IRE: national institute for radioelements; NTP: nuclear technology products radioisotopes; RIAR: the Research Institute of Atomic Reactors; and N.A: Not Available.

^bThe alkaline process is fully compatible with the U-Al alloy targets and offers the advantage of ¹³¹I co-production capability.

^cAvailable supply capacity: is the upper limit of ⁹⁹Mo supply capability that can be achieved on a routine operation framework.

^dAdditional ⁹⁹Mo supply capability owing to the engagement of a new processing facility, namely, ANSTO, Nuclear Medicine (ANM), which started in May 2019.

^eCurium was established through a merger between Mallinckrodt Nuclear Medicine and Ion Beam Applications Molecular (IBAM). http://www.mallinckrodt.com/about/news-and-media/2197068 (accessed 8.6.2022).

^fCNL/Nordion terminated their ⁹⁹Mo processing activities at the end of 2016.